Article info
PDFOriginal research
Predicting the Risk of nOdal disease with histological and Molecular features in Endometrial cancer: the prospective PROME trial
- Correspondence to Dr Giorgio Bogani, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; giorgiobogani{at}yahoo.it
Citation
Predicting the Risk of nOdal disease with histological and Molecular features in Endometrial cancer: the prospective PROME trial
Publication history
- Received February 27, 2024
- Accepted April 16, 2024
- First published April 23, 2024.
Online issue publication
September 02, 2024
Article Versions
- Previous version (23 April 2024).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.